<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805606</url>
  </required_header>
  <id_info>
    <org_study_id>A107_01PK2012</org_study_id>
    <nct_id>NCT04805606</nct_id>
  </id_info>
  <brief_title>A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843</brief_title>
  <official_title>A Randomized, Open-label, and Parallel Study to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843 in Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Open-label, and Parallel Study to Assess Pharmacokinetic/Pharmacodynamic&#xD;
      Profiles and Safety of CKD-843 in Male Volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 3, 2021</start_date>
  <completion_date type="Anticipated">February 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of CKD-843 A, CKD-843 B</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)</time_frame>
    <description>Area under the concentration-time curve from time zero to last</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of CKD-843 A, CKD-843 B</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)</time_frame>
    <description>Area under the concentration-time curve from zero up to ∞</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-90days of CKD-843 A, CKD-843 B</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)</time_frame>
    <description>Area under the concentration-time curve from time zero to 90 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of CKD-843-R</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)</time_frame>
    <description>Area under the concentration-time curve from time zero to last</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of CKD-843-R</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)</time_frame>
    <description>Area under the concentration-time curve from zero up to ∞</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-90days of CKD-843-R</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)</time_frame>
    <description>Area under the concentration-time curve from time zero to 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of CKD-843 A, CKD-843 B</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of CKD-843 A, CKD-843 B</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of CKD-843 A, CKD-843 B</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)</time_frame>
    <description>Apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of CKD-843 A, CKD-843 B</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CKD-843-R</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of CKD-843-R</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of CKD-843-R</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)</time_frame>
    <description>Apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of CKD-843-R</measure>
    <time_frame>Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alopecia</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-843 A - 27mg, Single Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-843 A - 45mg, Single Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-843 A - 56mg, Single Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-843 B - 45mg, Single Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CKD-843-R</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-843 A</intervention_name>
    <description>Single Dose</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-843 B</intervention_name>
    <description>Single Dose</description>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-843-R</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Those who aged between 19 to 50 inclusion of man who concerned about androgenic&#xD;
             alopecia.&#xD;
&#xD;
          -  Those who has body weight ≥ 50kg.&#xD;
&#xD;
          -  Those who has calculated body mass index(BMI) of 18.5 ≤ ~ &lt; 27.0 kg/m2&#xD;
&#xD;
               -  Body Mass Index, kg/m2= Body weight(kg)/[Height(m)2]&#xD;
&#xD;
          -  Those who consent to proper contraception and do not donate sperm until 6 months after&#xD;
             the last administration of investigational product.&#xD;
&#xD;
          -  Those who understanding the detailed description of this clinical trial and&#xD;
             voluntarily decide to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have clinically significant disease or medical history of Hepatopathy, Renal&#xD;
             dysfunction, Neurological disorder, Immunity disorder, Respiratory disorder,&#xD;
             Genitourinary system disorder, Hemato-oncology disorder, Cardiovascular disorder or&#xD;
             Psychical disorder&#xD;
&#xD;
          -  Those who have history of hypersensitivity to active pharmaceutical ingredient,&#xD;
             5α-reductase inhibitor, tocopherol.&#xD;
&#xD;
          -  Those who have the screening(D-28~D-2) test results written below&#xD;
&#xD;
               -  AST, ALT &gt; 1.25 times higher than upper normal level&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 times higher than upper normal level&#xD;
&#xD;
               -  eGFR (estimated Glomerular Filtration Rate, which is calculated by MDRD) &lt; 60&#xD;
                  mL/min/1.73m2&#xD;
&#xD;
               -  &quot;Positive&quot; or &quot;Reactive&quot; test result of Hepatitis B &amp; C, HIV, RPR&#xD;
&#xD;
               -  Under 5 min resting condition, systolic blood pressure &gt;150 mmHg or &lt;90 mmHg,&#xD;
                  diastolic blood pressure &gt;100 mmHg or &lt;50 mmHg&#xD;
&#xD;
          -  Those who have a drug abuse history within one year or positive reaction on urine drug&#xD;
             screening test.&#xD;
&#xD;
          -  Those who received following drugs, which may affect results of clinical trial and&#xD;
             safety Ethical-the-counter (ETC) drugs and herbal medicines within 14 days before the&#xD;
             first administration and Over-the-counter (OTC) drugs, health foods and vitamin&#xD;
             preparations within 7 days before the first administration of the investigational&#xD;
             product.&#xD;
&#xD;
          -  Those who take barbiturate and related (causing induction or inhibition of metabolism)&#xD;
             drug within 30 days before the first administration of investigational product.&#xD;
&#xD;
          -  Those who exceeding smoke consumption criteria or can't stop smoking during&#xD;
             hospitalization period.&#xD;
&#xD;
               -  Criteria: Smoke &gt; 10 cigarettes/day&#xD;
&#xD;
          -  Those who exceeding an alcohol and caffeine consumption criteria or can't stop&#xD;
             consuming alcohol and caffeine during hospitalization period.&#xD;
&#xD;
               -  Criteria: Caffeine &gt; 5 cups/day, Alcohol &gt; 210 g/week&#xD;
&#xD;
          -  Those who took grapefruit within 7 days before the first administration of&#xD;
             investigational product.&#xD;
&#xD;
          -  Those who received investigational product by participating in other clinical trial&#xD;
             within 6 months before the first administration of investigational product.&#xD;
&#xD;
          -  Those who donated whole blood within 60 days or apheresis within 30 days before the&#xD;
             first administration of investigational product.&#xD;
&#xD;
          -  Those who received transfusion within 30 days before the first administration of&#xD;
             investigational product.&#xD;
&#xD;
          -  Those who are deemed inappropriate to participate in clinical trial by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MinSoo Park, M.D. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MinSoo Park, M.D. Ph.D</last_name>
    <phone>+82-2-2228-0400</phone>
    <email>minspark@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Minsoo Park</last_name>
      <phone>(82-2) 2228-0400</phone>
      <email>minspark@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Minsoo Park, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

